Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 7/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10105334 | 0.84 | MAPT (0.42) | MAPTKMT2AMEN1NPSR1LMNA | |
| SCHEMBL17187258 | 0.83 | MAOA (0.48) | MAPTKMT2AMEN1NPSR1LMNA | |
| SCHEMBL12793382 | 0.83 | MAPT (0.40) | MAPTKMT2AMEN1NPSR1LMNA | |
| SCHEMBL12841613 | 0.83 | MEN1 (0.44) | MAPTKMT2AMEN1NPSR1LMNA | |
| SCHEMBL19885348 | 0.83 | MAPT (0.44) | MAPTKMT2AMEN1NPSR1LMNA | |
| SCHEMBL13511705 | 0.82 | MEN1 (0.39) | MAPTKMT2AMEN1NPSR1LMNA | |
| SCHEMBL12776322 | 0.80 | MAPT (0.38) | MAPTKMT2AMEN1NPSR1LMNA | |
| SCHEMBL1102446 | 0.79 | NR1H3 (0.42) | MAPTKMT2AMEN1NPSR1LMNA | |
| SCHEMBL15469131 | 0.79 | NR1H3 (0.46) | MAPTKMT2AMEN1NPSR1LMNA | |
| SCHEMBL28148118 | 0.79 | SMN1; SMN2 (0.43) | MAPTKMT2AMEN1NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240224547-A1 | PEROVSKITE PHOTODIODE AND IMAGE SENSOR AND ELECTRONIC DEVICE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-12022725-B2 | Electronic device, light-emitting device, electronic appliance, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-12022725-B2 | Electronic device, light-emitting device, electronic appliance, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-20240074308-A1 | ORTHO-SUBSTITUTED THERMALLY ACTIVATED DELAYED FLUORESCENCE MATERIAL AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| US-20240074308-A1 | ORTHO-SUBSTITUTED THERMALLY ACTIVATED DELAYED FLUORESCENCE MATERIAL AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | HIROSHIMA UNIVERSITY (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | HIROSHIMA UNIVERSITY (JP) | 2024-01-25 | — | — | US | disclosed |
| US-11840550-B2 | Silyl-biaryl phosphoramidites and methods of making | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230380274-A1 | ORTHO-SUBSTITUTED THERMALLY ACTIVATED DELAYED FLUORESCENCE MATERIAL AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-23 | — | — | US | disclosed |
| US-11758808-B2 | Ortho-substituted thermally activated delayed fluorescence material and organic light-emitting device comprising same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-09-12 | — | — | US | disclosed |
| US-20070259208-A1 | Electroluminescent materials and devices | MERCK PATENT GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070200096-A1 | Doped lithium quinolate | OLED-T LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| US-20070200096-A1 | Doped lithium quinolate | OLED-T LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| WO-2007080116-A2 | USE OF CNS PENETRATING ANTICANCER COMPOUNDS FOR THE TREATMENT OF PROTOZAN DISEASES | DORMEYER MATTHIAS (DE) | 2007-07-19 | — | — | WO | disclosed |
| EP-1808173-A1 | Use of CNS penetrating anticancer compounds for the treatment of protozan diseases | Dormeyer, Matthias (DE) | 2007-07-18 | — | — | EP | disclosed |
| US-20070135502-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW T | 2007-06-14 | — | — | US | disclosed |
| US-7183304-B2 | such as (R)-1-{4-[4-(4-Phenoxy-2-propyl-phenoxy)-butoxy]-benzenesulfonyl}-azetidine-2-carboxylic acid, used as peroxisome proliferator-activated receptor agonists; hypoglycemic agents | NOVARTIS AG (CH) | 2007-02-27 | — | — | US | disclosed |
| US-20070003788-A1 | Organic electroluminescence device | IDEMITSU KOSAN CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-20070003788-A1 | Organic electroluminescence device | IDEMITSU KOSAN CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | NOVARTIS AG (CH) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840550-B2 | Silyl-biaryl phosphoramidites and methods of making | PAICS, PGLS, SCLY | MAPT 3825/4885KMT2A 1728/4885MEN1 1703/4885 |
| US-12022725-B2 | Electronic device, light-emitting device, electronic appliance, and lighting device | EED, L1CAM, ALDH1A2 | MAPT 1989/4885KMT2A 461/4885MEN1 1223/4885 |
| US-20070135502-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | MAPT 3328/4885KMT2A 2522/4885MEN1 3603/4885 |
| US-20230380274-A1 | ORTHO-SUBSTITUTED THERMALLY ACTIVATED DELAYED FLUORESCENCE MATERIAL AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | TEAD2, TEAD3, TEAD4 | MAPT 756/4885KMT2A 2414/4885MEN1 4665/4885 |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | PPARG, GPR119, PPARA | MAPT 2511/4885KMT2A 1633/4885MEN1 3853/4885 |
| US-11758808-B2 | Ortho-substituted thermally activated delayed fluorescence material and organic light-emitting device comprising same | TEAD2, TEAD3, TEAD4 | MAPT 756/4885KMT2A 2414/4885MEN1 4665/4885 |
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | PIN1, ACE2, ACE | MAPT 261/4885KMT2A 3733/4885MEN1 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.